: The gut microbiota plays a fundamental role in Hepatitis C Virus (HCV)-related liver disease. Indeed, HCV infection alters the gut microbiota, whereas intestinal dysbiosis induces an underlying inflammatory state. This status may lead to liver disease progression. The advent of direct acting antivirals (DAAs) was a turning point in the history of HCV infection, which enhances the chances of recovery. Beyond the elimination of the virus, DAA therapy can affect the gut microbiota of the HCV patient. The study of the gut microbiota in the patient with HCV-related liver disease could be the first step in understanding the etiopathogenesis of hepatopathy thereby opening the way to new therapeutic opportunities. Herein we evaluate current knowledge regarding the gut microbiota in patients with HCV infection and the impact of DAA therapy.

Microbiota and hepatitis C virus in the era of direct-acting antiviral agents / Pinchera, Biagio; SCHIANO MORIELLO, Nicola; Buonomo, ANTONIO RICCARDO; Zappulo, Emanuela; Viceconte, Giulio; Villari, Riccardo; Gentile, Ivan. - In: MICROBIAL PATHOGENESIS. - ISSN 0882-4010. - 175:(2023), p. 105968. [10.1016/j.micpath.2023.105968]

Microbiota and hepatitis C virus in the era of direct-acting antiviral agents

Biagio Pinchera;Nicola Schiano Moriello;Antonio Riccardo Buonomo;Emanuela Zappulo;Giulio Viceconte;Riccardo Villari;Ivan Gentile
2023

Abstract

: The gut microbiota plays a fundamental role in Hepatitis C Virus (HCV)-related liver disease. Indeed, HCV infection alters the gut microbiota, whereas intestinal dysbiosis induces an underlying inflammatory state. This status may lead to liver disease progression. The advent of direct acting antivirals (DAAs) was a turning point in the history of HCV infection, which enhances the chances of recovery. Beyond the elimination of the virus, DAA therapy can affect the gut microbiota of the HCV patient. The study of the gut microbiota in the patient with HCV-related liver disease could be the first step in understanding the etiopathogenesis of hepatopathy thereby opening the way to new therapeutic opportunities. Herein we evaluate current knowledge regarding the gut microbiota in patients with HCV infection and the impact of DAA therapy.
2023
Microbiota and hepatitis C virus in the era of direct-acting antiviral agents / Pinchera, Biagio; SCHIANO MORIELLO, Nicola; Buonomo, ANTONIO RICCARDO; Zappulo, Emanuela; Viceconte, Giulio; Villari, Riccardo; Gentile, Ivan. - In: MICROBIAL PATHOGENESIS. - ISSN 0882-4010. - 175:(2023), p. 105968. [10.1016/j.micpath.2023.105968]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/906401
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact